JOHN L. HIGGINS - Corporate Board Profile

BIO-TECHNE Corp

Filing Date	Source Excerpt
2009-09-22	John L. Higgins 39 Director President and Chief 2009 Executive Officer of Ligand Pharmaceuticals Incorporated, since January 2007. Chief Financial Officer for Connetics Corporation from 1997 to 2007. Director of Ligand Pharmaceuticals Incorporated and BioCryst Pharmaceuticals, Inc.
2010-09-17	John L. Higgins 27,000 99,500 126,500
2011-09-16	John L. Higgins Age: 41 Role: Director Committees: Audit Committee, Executive Compensation Committee Compensation: $107,500 Excerpt: "Mr. Higgins has served on the Company’s Board since 2009..." and "2011 Director Compensation: John L. Higgins, $107,500 total compensation."
2012-09-14	John L. Higgins has served on the Company 27s Board since 2009. He graduated Magna Cum Laude with a bachelor 27s degree from Colgate University. Mr. Higgins has been President and Chief Executive Officer of Ligand Pharmaceuticals Incorporated since January 2007 and has been a member of Ligand 27s Board of Directors since March 2007. From 1997 until joining Ligand, Mr. Higgins was with Connetics Corporation, a specialty pharmaceutical company, as its Chief Financial Officer, and also served as Executive Vice President, Finance and Administration and Corporate Development at Connetics from January 2002 until its acquisition by Stiefel Laboratories, Inc. in December 2006. Mr. Higgins was previously a member of the executive management team at BioCryst Pharmaceuticals, Inc., a biopharmaceutical company. Currently, he is a Director of BioCryst and served as Chairperson of its Audit Committee from January 2011 to March 2012. Before joining BioCryst in 1994, Mr. Higgins was a member of the healthcare banking team of Dillon, Read & Co. Inc., an investment banking firm. Mr. Higgins also serves as Chairman of CoMentis, Inc., a biopharmaceutical company, and has served as a director of numerous public and private companies. Among other attributes, skills and qualifications, the Board believes Mr. Higgins is qualified to serve as a Director of the Company due to his combination of biopharmaceutical business, accounting and finance experience as well as his executive management experience, particularly with public companies.
2013-09-20	John L. Higgins has served on the Company 27s Board since 2009. He graduated Magna Cum Laude with a bachelor 27s degree from Colgate University. Mr. Higgins has been President and Chief Executive Officer of Ligand Pharmaceuticals Incorporated since January 2007 and has been a member of Ligand 27s Board of Directors since March 2007. From 1997 until joining Ligand, Mr. Higgins was with Connetics Corporation, a specialty pharmaceutical company, as its Chief Financial Officer, and also served as Executive Vice President, Finance and Administration and Corporate Development at Connetics from January 2002 until its acquisition by Stiefel Laboratories, Inc. in December 2006. Mr. Higgins was previously a member of the executive management team and a director at BioCryst Pharmaceuticals, Inc., a biopharmaceutical company. Before joining BioCryst in 1994, Mr. Higgins was a member of the healthcare banking team of Dillon, Read & Co. Inc., an investment banking firm. Mr. Higgins also serves as Chairman of CoMentis, Inc., a biopharmaceutical company, and has served as a director of numerous public and private companies. Among other attributes, skills and qualifications, the Board believes Mr. Higgins is qualified to serve as a Director of the Company due to his combination of biopharmaceutical business, accounting and finance experience as well as his executive management experience, particularly with public companies.
2014-09-19	John L. Higgins has served on the Companys Board since 2009. ... During fiscal 2014, the members of the Audit Committee were Mr. Higgins (Chair) ... John L. Higgins $220,640 total compensation.
2015-09-18	John L. Higgins, age 45, has served on the Company’s Board since 2009. ... Mr. Higgins has been President and Chief Executive Officer of Ligand Pharmaceuticals, Inc. since January 2007. ... The Board believes Mr. Higgins is qualified to serve as a Director of the Company due to his combination of biopharmaceutical business, accounting and finance experience as well as his executive management experience, particularly with public companies.
2016-09-13	John L. Higgins, age 46, has served on the Company’s Board since 2009. ... The Board currently has three standing Committees: the Audit Committee, the Executive Compensation Committee and the Nominations and Governance Committee. ... The membership of each standing committee during FY 2016 ... John L. Higgins: Audit (Chair), Executive Compensation. ... Directors who are not employees of the Company were compensated for FY 2016 as follows: John L. Higgins total $262,979.
2017-09-12	Mr. Higgins has been President and CEO of Ligand Pharmaceuticals... The Board has determined that, for FY 2017, Messrs. Baumgartner and Higgins are “audit committee financial experts”... Director Compensation for FY 2017: John L. Higgins total $272,486.
2018-09-11	Mr. John Higgins has been President and CEO of Ligand Pharmaceuticals... Board believes Mr. Higgins is qualified... Chair of Audit Committee and member of Executive Compensation Committee. Director Compensation Table shows total $273,385.
2019-09-09	John L. Higgins Age: 49 Independent Director Since: 2009 Other Public Directorships: Ligand Pharmaceuticals, Inc. Mr. Higgins offers the Board over 20 years of industry experience through his role as Chief Executive Officer of Ligand Pharmaceuticals and leadership roles in other pharmaceutical companies. His role with Ligand has given him vital experience in the application of strategic leadership skills within our industry, as well as extensive public company executive and board experience. Mr. Higgins also brings to the Board deep knowledge in accounting and financial matters. Director Compensation for FY 2019 John L. Higgins Total: $277,427
2020-09-15	John L. Higgins Age: 50 Independent Director Since: 2009 Chair of Audit Committee Member of Science & Technology Committee Director Compensation for FY 2020: $298,759
2022-09-14	John L. Higgins Age: 52 Director since: 2009 INDEPENDENT ...Committee Membership John L. Higgins ...Board Committees John L. Higgins Audit Committee: Chair ...Director Compensation John L. Higgins Total ($): 300,144
2023-09-13	John L. Higgins Age: 53 Director since: 2009 INDEPENDENT Committees: • Audit (chair) • Nominations & Governance Compensation Paid to the Non-Employee Directors John L. Higgins $300,298
2024-09-12	John L. Higgins Age: 54 Director since: 2009 INDEPENDENT Committees: Audit (chair) Nominations & Governance ...Mr. Higgins offers the Board over 20 years of industry experience through his role as Chief Executive Officer of Ligand Pharmaceuticals and leadership roles in other pharmaceutical companies. ...Compensation Paid to the Non-Employee Directors John L. Higgins Fees Earned or Paid in Cash: $100,000 Stock Awards: $99,954 Option Awards: $100,010 All Other Compensation: $498 Total: $300,462

LIGAND PHARMACEUTICALS INC

Filing Date	Source Excerpt
2014-04-21	John L. Higgins 2013 500,331 559,360 1,567,129 375,248 2,843 3,004,911 ... John L. Higgins is President, Chief Executive Officer and a member of the board of directors of Ligand Pharmaceuticals Incorporated. ... Our board of directors has determined that, with the exception of Mr. Higgins, each of the directors is an independent director under the NASDAQ Global Market listing standards.
2015-03-13	John L. Higgins - Chief Executive Officer and Director, Age 44. No specific director compensation listed.
2016-04-12	John L. Higgins is the Chief Executive Officer of Ligand Pharmaceuticals Incorporated, a position he has held since January 2007 and he has been a member of Ligand’s board of directors since March 2007. ... Our board of directors has determined that, with the exception of Mr. Higgins, each of the directors is an independent director under the NASDAQ Global Market listing standards.
2017-04-14	John L. Higgins Chief Executive Officer and Director 2007 47 ... The following table provides information regarding the compensation earned by our named executive officers during the fiscal years ended December 31, 2016. ... John L. Higgins 2016 573,958 1,992,215 2,393,068 387,421 5,978 5,352,640 ... John L. Higgins, 47, is being considered for the position of director of the Company.
2018-04-30	John L. Higgins Chief Executive Officer and Director 2007 48; No committee memberships listed; Compensation details not listed for director role.
2019-04-24	John L. Higgins 49 2007 Chief Executive Officer of Ligand Pharmaceuticals Incorporated ... Mr. Higgins serves on the board, audit and governance committees of BioTechne Corporation, a company which develops and manufactures proteins.
2020-04-24	John L. Higgins 50 2007 Chief Executive Officer of Ligand Pharmaceuticals Incorporated ... Mr. Higgins serves on the board, audit committee and nominations & governance committee of Bio-Techne Corporation, a publicly-traded life sciences services. Mr. Higgins has served as a director on numerous public and private companies. ... John L. Higgins is our Chief Executive Officer, a position he has held since January 2007 and he has been a member of our board of directors since March 2007.
2021-04-23	John L. Higgins is our Chief Executive Officer, a position he has held since January 2007 and he has been a member of our board of directors since March 2007. Prior to joining our company, Mr. Higgins served as Chief Financial Officer at Connetics Corporation, a specialty pharmaceutical company, since 1997, and also served as Executive Vice President, Finance and Administration and Corporate Development at Connetics until its acquisition by Stiefel Laboratories, Inc. in December 2006. Before joining Connetics, he was a member of the executive management team at BioCryst Pharmaceuticals. Prior to BioCryst, Mr. Higgins was a member of the healthcare banking team of Dillon, Read & Co. Inc., an investment banking firm. Mr. Higgins serves on the board, audit committee and nominations & governance committee of Bio-Techne Corporation, a publicly-traded life sciences services. Mr. Higgins has served as a director on numerous public and private companies. He also serves as the chairperson of the board of trustees of Academy of Whole Learning, a non-profit organization dedicated to providing educational and therapy services to children of underrepresented communities. He graduated Magna Cum Laude from Colgate University with an A.B. in economics. Mr. Higgins’ executive experience operating and managing public biotechnology companies, his prior service on other company boards and his financial transaction experience as an investment banker in the biopharmaceutical industry contributed to our board of directors’ conclusion that he should serve as a director of our company.
2022-04-22	John L. Higgins is our Chief Executive Officer, a position he has held since January 2007 and he has been a member of our board of directors since March 2007. Mr. Higgins is our only employee director and receives no compensation for his service as a member of the board. His compensation is described under Executive Compensation and Other Information.